Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma

Approved histone deacetylase (HDAC) inhibitors have low efficacy against the most commonly-diagnosed non-Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), but the mechanisms underlying clinical resistance are poorly understood. Using a DLBCL cell-based model, we previously demonstrated that r...

Descripció completa

Dades bibliogràfiques

Autors principals:	Aaron P. Havas, Ana A. Tula-Sanchez, Hailey M. Steenhoek, Anvi Bhakta, Taylor Wingfield, Matthew J. Huntley, Angela S. Nofal, Tasmia Ahmed, Rosa Jaime-Frias, Catharine L. Smith
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-01-01
Col·lecció:	Translational Oncology
Matèries:	Histone deacetylase Lymphoma Cell cycle Apoptosis Therapeutic resistance
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1936523323001651
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!